Tucidinostat (Chidamide) is being evaluated in numerous clinical trials from Phase I through Phase IV across recruiting, completed, and terminated statuses. Sponsored by academic centers including Sun Yat-sen University and Ruijin Hospital alongside pharmaceutical developers such as Chipscreen Biosciences and HUYABIO International, these studies assess Tucidinostat as monotherapy or combined with agents like pembrolizumab. Key indications studied include peripheral T-cell lymphoma, diffuse large B-cell lymphoma, HR+/HER2- breast cancer, non-small cell lung cancer, cervical cancer, and neuroblastoma.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06947967 | RECRUITING | Lymphoma, T-Cell, Peripheral |
Chipscreen Biosciences, Ltd. |
2025-08-12 | PHASE3 |
| NCT05088226 | RECRUITING | Peripheral Blood Stem Cell Transplantation |
Chinese PLA General Hospital |
2021-12-01 | PHASE2 |
| NCT07598578 | RECRUITING | Peripheral T-Cell Lymphoma Refractory |
Second Affiliated Hospital of Soochow University |
2026-06-01 | EARLY_PHASE1 |
| NCT06890585 | NOT_YET_RECRUITING | BTK Inhibitors; Histone Deacetylase Inhibitor; Double Express Diffuse Large B-cell Lymphoma |
Li Zhiming |
2025-06-01 | PHASE2 |
| NCT06674096 | RECRUITING | Double-expressor Lymphoma |
Zhejiang Cancer Hospital |
2024-11-06 | PHASE2 |
| NCT07493148 | RECRUITING | Diffuse Large B-Cell Lymphoma (DLBCL) |
Ou Bai, MD/PHD |
2026-04-30 | PHASE2 |
| NCT07493330 | NOT_YET_RECRUITING | PTCL; Refractory |
Ruijin Hospital |
2026-03-23 | PHASE1; PHASE2 |
| NCT07493109 | RECRUITING | Diffuse Large B-Cell Lymphoma (DLBCL) |
Ou Bai, MD/PHD |
2026-05-30 | PHASE3 |
| NCT07072221 | RECRUITING | Peripheral T-cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2024-11-01 | |
| NCT04025450 | RECRUITING | Multiple Myeloma |
The First Affiliated Hospital of Soochow University |
2019-07-15 | PHASE1; PHASE2 |
| NCT07507318 | RECRUITING | Diffuse Large B-Cell Lymphoma |
Rong Tao |
2026-06-16 | PHASE2 |
| NCT07521124 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML) in Remission |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2026-06-01 | |
| NCT07542912 | NOT_YET_RECRUITING | Complete Remission Rate， CRR; Progression Free Survival; Overall Survival; Adverse Event; Duration of Response |
Sun Yat-sen University |
2026-06-01 | |
| NCT07380984 | RECRUITING | Natural Killer/T-cell Lymphoma |
Ruijin Hospital |
2026-03 | PHASE2 |
| NCT06084819 | RECRUITING | Relapsed/Refractory Acute Myeloid Leukemia |
Chinese PLA General Hospital |
2023-08-01 | PHASE2 |
| NCT07318831 | RECRUITING | Neuroblastoma (NB); Neuroblastoma in Children |
Tianjin Medical University Cancer Institute and Hospital |
2026-01-06 | PHASE2 |
| NCT07754890 | RECRUITING | Cutaneous T-cell Lymphoma (CTCL) |
Peking Union Medical College Hospital |
2025-08-26 | PHASE1; PHASE2 |
| NCT07635992 | NOT_YET_RECRUITING | HIV (Human Immunodeficiency Virus) |
First Affiliated Hospital of Zhejiang University |
2026-06-01 | PHASE1 |
| NCT06757387 | NOT_YET_RECRUITING | Peripheral T-cell Lymphoma |
Peking University Cancer Hospital & Institute |
2024-12-30 | PHASE1; PHASE2 |
| NCT06516978 | NOT_YET_RECRUITING | Diffuse Large B Cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2024-10-01 | PHASE2 |
| NCT07159620 | RECRUITING | Adult T-cell Leukemia/Lymphoma |
The First Affiliated Hospital of Soochow University |
2025-09-01 | PHASE2 |
| NCT07774377 | NOT_YET_RECRUITING | T-Cell Acute Lymphoblastic Leukemia; T-Cell Lymphoblastic Lymphoma |
First Affiliated Hospital of Zhejiang University |
2026-08-15 | PHASE3 |
| NCT07168317 | RECRUITING | New Diagnosed Angioimmunoblastic T-Cell Lymphoma |
The Affiliated Hospital of Xuzhou Medical University |
2025-08-01 | PHASE2 |
| NCT07074457 | RECRUITING | CD30+ Peripheral T-cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2024-11-01 | |
| NCT07746245 | NOT_YET_RECRUITING | Peripheral T-Cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2026-08-01 | PHASE2 |
| NCT07397832 | RECRUITING | Diffuse Large B-Cell Lymphoma (DLBCL) |
Tianjin Medical University Cancer Institute and Hospital |
2026-02-03 | PHASE2 |
| NCT07643636 | NOT_YET_RECRUITING | AML (Acute Myeloid Leukemia) |
Dongguan People's Hospital |
2026-06-30 | PHASE2 |
| NCT06497985 | RECRUITING | Colorectal Cancer |
Chipscreen Biosciences, Ltd. |
2024-12-06 | PHASE3 |
| NCT07601607 | NOT_YET_RECRUITING | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) |
Sun Yat-sen University |
2026-05-30 | PHASE1; PHASE2 |
| NCT07058103 | RECRUITING | Angioimmunoblastic T-Cell Lymphoma Recurrent; Angioimmunoblastic T-Cell Lymphoma Refractory |
The Affiliated Hospital of Xuzhou Medical University |
2025-04-01 | PHASE2 |
| NCT07415980 | NOT_YET_RECRUITING | Double Expressor DLBCL |
Sun Yat-sen University |
2026-04-01 | PHASE1; PHASE2 |
| NCT07412262 | RECRUITING | Non-Small Cell Lung Cancer |
Guangdong Association of Clinical Trials |
2026-08-28 | PHASE2 |
| NCT07783100 | RECRUITING | Relapsed or Refractory Acute Myeloid Leukemia |
The First Affiliated Hospital of Xiamen University |
2026-11-11 | PHASE2 |
| NCT07518602 | RECRUITING | Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) |
Sun Yat-sen University |
2026-03-27 | PHASE2 |
| NCT07339527 | NOT_YET_RECRUITING | Mature T-cell and NK-cell Lymphoma |
Sun Yat-sen University |
2026-01-01 | PHASE1; PHASE2 |
| NCT07706959 | NOT_YET_RECRUITING | Peripheral T-cell Lymphoma (PTCL) |
Ruijin Hospital |
2026-07 | PHASE1; PHASE2 |
| NCT06776952 | RECRUITING | Relapsed/Refractory Peripheral T Cell Lymphoma |
Evopoint Biosciences Inc. |
2025-04-10 | PHASE3 |
| NCT06158386 | RECRUITING | Follicular Lymphoma; Refractory B-Cell Lymphoma; Relapsed Non-Hodgkin Lymphoma |
The First Affiliated Hospital of Xiamen University |
2023-11-22 | PHASE2 |
| NCT05270200 | RECRUITING | Leukemia, Myeloid, Acute |
Zhujiang Hospital |
2022-02-01 | PHASE1; PHASE2 |
| NCT07538180 | ACTIVE_NOT_RECRUITING | Newly Diagnosed MYC/BCL2 Double-expressor DLBCL |
Sun Yat-sen University |
2025-10-30 | PHASE2 |
| NCT06550336 | ACTIVE_NOT_RECRUITING | Peripheral T Cell Lymphoma |
The First Hospital of Jilin University |
2024-06-30 | PHASE2 |
| NCT04668690 | ACTIVE_NOT_RECRUITING | Peripheral T Cell Lymphoma |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2021-04-13 | PHASE3 |
| NCT06386302 | RECRUITING | AML; Acute Myeloid Leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
2024-08-05 | |
| NCT05678933 | ENROLLING_BY_INVITATION | Peripheral T-cell Lymphoma Targeted Therapy |
Tianjin Medical University Cancer Institute and Hospital |
2023-01-01 | PHASE3 |
| NCT07234162 | RECRUITING | Peripheral T-cell Lymphoma |
Dizal Pharmaceuticals |
2024-05-13 | PHASE3 |
| NCT07514936 | RECRUITING | Newly Diagnosed Acute Myeloid Leukemia (AML); Elderly Patients |
Chinese PLA General Hospital |
2024-11-18 | PHASE3 |
| NCT07139353 | NOT_YET_RECRUITING | Peripheral T Cells Lymphoma (PTCL) |
Sun Yat-sen University |
2025-09-15 | PHASE1; PHASE2 |
| NCT07133763 | NOT_YET_RECRUITING | EBV-Associated Lymphoproliferative Disorders; PD-1 Inhibitor; Tenofovir; Chidamide; Lenalidomide |
The Affiliated Hospital of Xuzhou Medical University |
2025-09-01 | PHASE1; PHASE2 |
| NCT07133776 | NOT_YET_RECRUITING | Epstein-Barr Virus (EBV) Infection; PD-1 Inhibitor; Tenofovir; Chidamide; Lenalidomide |
The Affiliated Hospital of Xuzhou Medical University |
2025-09-01 | PHASE1; PHASE2 |
| NCT06891157 | RECRUITING | Chidamide; R-CHOP Chemotherapy; DLBCL - Diffuse Large B Cell Lymphoma; Double-expressor Lymphoma (DEL) |
The First Affiliated Hospital with Nanjing Medical University |
2024-08-20 | PHASE2 |
| NCT07093710 | RECRUITING | Peripheral T Cell Lymphoma |
Sun Yat-sen University |
2025-08-27 | PHASE1; PHASE2 |
| NCT06532552 | RECRUITING | Acute Myeloid Leukemia, Adult; Newly Diagnosed |
The First Affiliated Hospital of Soochow University |
2024-07-29 | PHASE2 |
| NCT07545967 | RECRUITING | Head and Neck Squamous Cell Carcinoma HNSCC |
West China Hospital |
2026-04-23 | PHASE1 |
| NCT07570849 | RECRUITING | Intrahepatic Cholangiocarcinoma |
Shanghai Zhongshan Hospital |
2026-03-01 | PHASE2 |
| NCT06393361 | RECRUITING | Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma |
Chinese PLA General Hospital |
2024-06-01 | PHASE2 |
| NCT05833724 | RECRUITING | Relapsed or Refractory Peripheral T-cell Lymphoma |
Great Novel Therapeutics Biotech & Medicals Corporation |
2024-10-18 | PHASE2 |
| NCT07552324 | NOT_YET_RECRUITING | DHL; THL; DLBCL - Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2026-05-01 | PHASE2 |
| NCT06421948 | RECRUITING | Peripheral T-cell Lymphoma |
Yanyan Liu |
2024-05-25 | PHASE1; PHASE2 |
| NCT07489989 | RECRUITING | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) |
Daihong Liu |
2025-05-15 | PHASE2 |
| NCT06951997 | RECRUITING | Metastatic Pancreatic Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2025-03-07 | PHASE2 |
| NCT07577986 | NOT_YET_RECRUITING | HIV (Human Immunodeficiency Virus) |
First Affiliated Hospital of Zhejiang University |
2026-05-01 | PHASE1; PHASE2 |
| NCT06930118 | RECRUITING | Advanced Colorectal Cancer in the Third-line Treatment and Beyond; pMMR/MSS Advanced Colorectal Cancer |
Shanghai Changzheng Hospital |
2025-04-10 | PHASE2 |
| NCT06671717 | NOT_YET_RECRUITING | Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma |
Peking University People's Hospital |
2024-12 | |
| NCT07616336 | NOT_YET_RECRUITING | Myelodysplastic Syndromes |
Zhongshan Hospital (Xiamen), Fudan University |
2026-07-01 | PHASE2 |
| NCT07320963 | NOT_YET_RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2026-03-31 | PHASE1; PHASE2 |
| NCT06745193 | NOT_YET_RECRUITING | Advanced Esophageal Carcinoma |
Peking University |
2025-02-01 | PHASE2 |
| NCT06570447 | RECRUITING | Diffuse Large B-Cell Lymphoma-Recurrent; Diffuse Large B-Cell Lymphoma-Refractory |
Tianjin Medical University Cancer Institute and Hospital |
2025-02-27 | PHASE2 |
| NCT06556862 | NOT_YET_RECRUITING | HR+/HER2- Advanced Breast Cancer |
Beijing 302 Hospital |
2025-10-01 | PHASE2 |
| NCT07304232 | RECRUITING | Allogeneic Hematopoietic Cell Transplantation (HCT); AML (Acute Myeloid Leukemia) |
Institute of Hematology & Blood Diseases Hospital, China |
2025-09-01 | PHASE2 |
| NCT05029141 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Refractory Acute Leukemia; Relapsed Adult AML |
The First Affiliated Hospital of Soochow University |
2021-09-01 | PHASE2 |
| NCT06764017 | RECRUITING | Diffuse Large B-Cell Lymphoma |
First Affiliated Hospital of Ningbo University |
2025-02-01 | PHASE2 |
| NCT05603884 | RECRUITING | Leukemia, Myeloid, Acute; AML Stage, Adult |
The First Affiliated Hospital of Xiamen University |
2022-12-01 | PHASE2 |
| NCT06255795 | NOT_YET_RECRUITING | Extranodal Natural Killer T Cell Lymphoma |
Ruijin Hospital |
2024-02-15 | PHASE3 |
| NCT06151106 | RECRUITING | Peripheral T Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma; Refractory T-Cell Lymphoma |
The First Affiliated Hospital of Xiamen University |
2023-11-22 | PHASE2 |
| NCT06739395 | RECRUITING | Solid Tumor; Precision Medicine |
Tianjin Medical University Second Hospital |
2024-11-01 | PHASE2 |
| NCT05958719 | RECRUITING | Peripheral T Cell Lymphoma; Epigenetic Repression |
Institute of Hematology & Blood Diseases Hospital, China |
2023-03-02 | PHASE2 |
| NCT06451861 | RECRUITING | Acute Myeloid Leukemia |
Guangdong Provincial People's Hospital |
2024-08-21 | PHASE2 |
| NCT06220162 | RECRUITING | Acute Myeloid Leukemia |
The First Affiliated Hospital of Soochow University |
2024-02-01 | PHASE2 |
| NCT06750991 | NOT_YET_RECRUITING | DLBCL |
Ruijin Hospital |
2024-12-31 | PHASE2 |
| NCT04512534 | RECRUITING | Peripheral T-cell Lymphoma |
Fudan University |
2020-11-13 | PHASE2 |
| NCT06701357 | RECRUITING | DLBCL |
Ruijin Hospital |
2024-12-10 | PHASE2 |
| NCT04985890 | NOT_YET_RECRUITING | HIV-1-infection |
UBP Greater China (Shanghai) Co., Ltd |
2024-03 | PHASE2 |
| NCT06066905 | RECRUITING | AML, Adult; Minimal Residual Disease |
Guangdong Provincial People's Hospital |
2023-10-26 | |
| NCT07373964 | RECRUITING | Small Cell Lung Cancer |
China Medical University, China |
2025-10-15 | PHASE2 |
| NCT05976997 | RECRUITING | Newly Diagnosed Peripheral T-cell Lymphoma |
Liling Zhang |
2023-05-08 | PHASE2 |
| NCT05566054 | RECRUITING | Acute Monocytic Leukemia; Newly Diagnosed |
The First Affiliated Hospital of Soochow University |
2022-03-01 | PHASE2 |
| NCT06563778 | NOT_YET_RECRUITING | Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma |
Chinese PLA General Hospital |
2024-09-01 | PHASE2 |
| NCT06979908 | RECRUITING | Metastatic Colorectal Cancer |
The First Hospital of Jilin University |
2025-01-22 | PHASE2 |
| NCT07081607 | NOT_YET_RECRUITING | Peripheral T-Cell Lymphoma, Not Classified |
Ruijin Hospital |
2025-07-15 | PHASE2 |
| NCT05675813 | RECRUITING | Peripheral T Cell Lymphoma |
Ruijin Hospital |
2023-02-13 | PHASE1; PHASE2 |
| NCT05983107 | RECRUITING | HR+/HER2- Advanced Breast Cancer; Targeted Therapy |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2023-07-20 | PHASE2 |
| NCT06584227 | RECRUITING | Pancreatic Cancer, Adult |
Liu Xiufeng |
2024-09-10 | PHASE2 |
| NCT06547476 | NOT_YET_RECRUITING | Breast Cancer |
Guangdong Provincial People's Hospital |
2024-09-01 | PHASE2 |
| NCT05890287 | RECRUITING | HR Positive HER2 Negative Advanced Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-05-16 | |
| NCT06122389 | RECRUITING | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy |
Jiangsu HengRui Medicine Co., Ltd. |
2024-02-05 | PHASE3 |
| NCT07651475 | ACTIVE_NOT_RECRUITING | R/R AML |
Liping Dou |
2026-03-31 | PHASE2 |
| NCT05931263 | RECRUITING | Newly Diagnosed Peripheral T-cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2023-06-01 | PHASE3 |
| NCT05305859 | RECRUITING | Leukemia, Myeloid, Acute; Relapsed Adult AML; Refractory Leukemia |
The First Affiliated Hospital of Xiamen University |
2022-01-12 | PHASE2 |
| NCT06858969 | NOT_YET_RECRUITING | Metastatic Colorectal Cancer |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2025-04-09 | PHASE2 |
| NCT05881265 | RECRUITING | APL |
Shanghai Jiao Tong University School of Medicine |
2023-05-15 | PHASE2 |
| NCT05768503 | RECRUITING | Metastatic Microsatellite-stable Colorectal Cancer |
Sun Yat-sen University |
2023-03-01 | PHASE3 |
| NCT06220487 | RECRUITING | Acute Lymphoblastic Leukemia; Philadelphia Chromosome; Philadelphia-Positive ALL; Adult ALL; IKZF1 Gene Mutation |
Nanfang Hospital, Southern Medical University |
2024-02-01 | PHASE2 |
| NCT06750848 | NOT_YET_RECRUITING | Advanced Breast Cancer |
Jundong Wu |
2024-12-20 | PHASE2 |
| NCT06492629 | UNKNOWN | PTCL |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2024-04-03 | PHASE2 |
| NCT05586841 | COMPLETED | HR+/HER2- Advanced Breast Cancer |
Beijing 302 Hospital |
2022-10-01 | PHASE1 |
| NCT05466318 | UNKNOWN | Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell |
Sichuan University |
2022-07-01 | PHASE3 |
| NCT06218888 | NOT_YET_RECRUITING | Colo-rectal Cancer |
Fujian Cancer Hospital |
2024-06-01 | PHASE2 |
| NCT06902038 | NOT_YET_RECRUITING | HIV-1 Infection |
Jun Chen, MD |
2025-03-22 | |
| NCT06685276 | RECRUITING | Colorectal Cancer Metastatic |
Dai, Guanghai |
2024-08-16 | PHASE2 |
| NCT04025931 | COMPLETED | Sarcoma |
Sun Yat-sen University |
2020-01-19 | PHASE2 |
| NCT06211881 | UNKNOWN | Relapsed/Refractory Peripheral T-cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2023-10-25 | |
| NCT06709885 | RECRUITING | Colon Adenocarcinoma |
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
2024-10-15 | PHASE2 |
| NCT06928376 | RECRUITING | Acute Myeloid Leukemia; First Line Therapy |
Chinese PLA General Hospital |
2024-04-18 | PHASE2 |
| NCT05186012 | UNKNOWN | NHL, Adult |
Ascentage Pharma Group Inc. |
2022-06-14 | PHASE1; PHASE2 |
| NCT05807659 | UNKNOWN | Myeloid Malignancies |
Sichuan University |
2023-03-16 | PHASE2 |
| NCT05991973 | COMPLETED | T Lymphoblastic Leukemia/Lymphoma |
Zhejiang University |
2023-07-15 | PHASE2 |
| NCT05348213 | RECRUITING | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2022-05-16 | PHASE2 |
| NCT06408623 | UNKNOWN | Liver Cancer |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2024-05-15 | PHASE2 |
| NCT05335473 | UNKNOWN | HR Positive HER2 Negative Advanced Breast Cancer |
Henan Cancer Hospital |
2022-05-13 | PHASE1; PHASE2 |
| NCT03031262 | ACTIVE_NOT_RECRUITING | AML |
Institute of Hematology & Blood Diseases Hospital, China |
2017-02-08 | PHASE1; PHASE2 |
| NCT05464173 | UNKNOWN | Breast Cancer |
Biyun Wang, MD |
2022-07-01 | PHASE1; PHASE2 |
| NCT05770882 | TERMINATED | Hepatocellular Carcinoma (HCC) |
Great Novel Therapeutics Biotech & Medicals Corporation |
2023-04-25 | PHASE1; PHASE2 |
| NCT05896813 | UNKNOWN | Newly Diagnosed Peripheral T-cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2023-03-01 | |
| NCT06637007 | RECRUITING | Sarcoma,Soft Tissue; Sarcoma; Sarcoma of Bone |
Shanxi Province Cancer Hospital |
2024-08-01 | PHASE2 |
| NCT06087419 | UNKNOWN | Acute Lymphoblastic Leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
2023-10-30 | PHASE1; PHASE2 |
| NCT04052659 | UNKNOWN | Peripheral T-cell Lymphoma |
Peking University |
2021-04-15 | PHASE2 |
| NCT05633914 | UNKNOWN | HR+/HER2- Breast Cancer |
Hunan Cancer Hospital |
2023-02-07 | PHASE2 |
| NCT06125171 | UNKNOWN | Osteosarcoma |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2024-01 | PHASE2 |
| NCT05519865 | COMPLETED | Non Small Cell Lung Cancer |
Chipscreen Biosciences, Ltd. |
2022-10-26 | PHASE2 |
| NCT05632848 | COMPLETED | Triple Negative Breast Cancer |
Sun Yat-sen University |
2022-06-15 | PHASE2 |
| NCT06083701 | UNKNOWN | Peripheral T Cell Lymphoma |
Peking Union Medical College Hospital |
2023-09-25 | PHASE1; PHASE2 |
| NCT05527912 | UNKNOWN | Double Express Diffuse Large B-cell Lymphoma |
Sun Yat-sen University |
2023-02-24 | PHASE2 |
| NCT05951855 | UNKNOWN | Acute Myeloid Leukemia (Relapsed/Refractory) |
The First Affiliated Hospital of Soochow University |
2023-03-01 | PHASE2 |
| NCT05572983 | UNKNOWN | Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype |
Sun Yat-sen University |
2022-09-01 | PHASE2 |
| NCT05527275 | UNKNOWN | Relapsed and Refractory Peripheral T-cell Lymphoma |
Sun Yat-sen University |
2022-10-01 | PHASE1; PHASE2 |
| NCT04562311 | ACTIVE_NOT_RECRUITING | Bladder Cancer Stage IV |
Sun Yat-sen University |
2021-01-01 | PHASE2 |
| NCT04661943 | COMPLETED | Diffuse Large B-cell Lymphoma |
Ou Bai, MD/PHD |
2017-06-01 | PHASE2 |
| NCT06037239 | UNKNOWN | Cutaneous T-cell Lymphoma |
Peking Union Medical College Hospital |
2023-07-01 | PHASE1; PHASE2 |
| NCT05083208 | TERMINATED | Peripheral T-Cell Lymphoma |
Henan Cancer Hospital |
2022-02-20 | PHASE1 |
| NCT05370547 | UNKNOWN | Non Hodgkin's Lymphoma |
Chinese PLA General Hospital |
2022-05-25 | PHASE1; PHASE2 |
| NCT05338541 | UNKNOWN | Neuroblastoma in Children |
Yizhuo Zhang |
2022-05-27 | PHASE1 |
| NCT05075681 | UNKNOWN | Peripheral Blood Stem Cell Transplantation |
Chinese PLA General Hospital |
2021-11-01 | PHASE1; PHASE2 |
| NCT05367856 | UNKNOWN | T Cell Lymphoma |
Ruijin Hospital |
2022-05-28 | PHASE2 |
| NCT05140616 | UNKNOWN | Safety and Efficacy |
The First Affiliated Hospital of Soochow University |
2021-05-31 | PHASE1; PHASE2 |
| NCT06068621 | COMPLETED | Acute Myeloid Leukemia |
Chinese PLA General Hospital |
2023-03-01 | PHASE2 |
| NCT05075460 | UNKNOWN | T-cell Lymphoma |
Peking Union Medical College Hospital |
2021-10-01 | PHASE3 |
| NCT05806047 | UNKNOWN | Hormone Receptor-positive Advanced Breast Cancer |
Fudan University |
2023-05-01 | PHASE2 |
| NCT04337606 | UNKNOWN | Non Hodgkin Lymphoma |
Chinese PLA General Hospital |
2020-04-04 | PHASE1; PHASE2 |
| NCT05411380 | UNKNOWN | Breast Cancer |
wang shusen |
2022-10-03 | PHASE2 |
| NCT05320640 | UNKNOWN | Relapsed/Refractory Non-Hodgkin Lymphoma; Advanced Solid Tumors |
Chinese PLA General Hospital |
2022-03-30 | PHASE1; PHASE2 |
| NCT05559008 | UNKNOWN | Peripheral T Cell Lymphoma |
Ruijin Hospital |
2022-09-30 | PHASE1; PHASE2 |
| NCT05281276 | TERMINATED | Metastatic Colorectal Cancer |
Taipei Medical University Shuang Ho Hospital |
2022-09-20 | PHASE1 |
| NCT05390476 | UNKNOWN | Triple Negative Breast Cancer |
wang shusen |
2022-08-01 | PHASE2 |
| NCT04233294 | UNKNOWN | Hodgkin Lymphoma |
Chinese PLA General Hospital |
2020-02-02 | PHASE2 |
| NCT05179213 | UNKNOWN | Angioimmunoblastic T-cell Lymphoma |
Peking Union Medical College Hospital |
2022-01-01 | PHASE2 |
| NCT05784987 | UNKNOWN | Diffuse Large B-cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2023-04-15 | |
| NCT05186545 | UNKNOWN | Breast Cancer; Breast Cancer Female |
The First Affiliated Hospital of Zhengzhou University |
2022-07-01 | PHASE2 |
| NCT05823701 | UNKNOWN | Diffuse Large B-Cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2022-09-30 | PHASE2 |
| NCT05682755 | RECRUITING | Leukemia, Myeloid, Acute |
Sichuan University |
2022-12-22 | PHASE1; PHASE2 |
| NCT04999540 | UNKNOWN | Breast Cancer |
Guangdong Women and Children Hospital |
2021-11-01 | PHASE2 |
| NCT05163483 | UNKNOWN | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma |
Ruihua Xu |
2022-07-01 | PHASE2 |
| NCT05438706 | UNKNOWN | Triple-negative Breast Cancer |
Fudan University |
2022-07-10 | PHASE2 |
| NCT05085626 | UNKNOWN | Advanced HER2 Negative Breast Carcinoma; HRD+Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-02-08 | PHASE2 |
| NCT05411874 | UNKNOWN | Thrombocytopenia |
Shandong University |
2022-10-01 | PHASE2 |
| NCT04465097 | COMPLETED | Breast Cancer |
First Affiliated Hospital, Sun Yat-Sen University |
2020-07-08 | PHASE2 |
| NCT05808582 | UNKNOWN | Hormone Receptor-positive Advanced Breast Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2023-05-01 | PHASE2 |
| NCT04994210 | UNKNOWN | Safety and Efficacy |
Sun Yat-sen University |
2021-10-04 | PHASE2 |
| NCT03564470 | UNKNOWN | Leukemia; Leukemia, Acute; Leukemia, Lymphoblastic; Leukemia, B-cell |
Nanfang Hospital, Southern Medical University |
2016-02-14 | PHASE2; PHASE3 |
| NCT05659992 | COMPLETED | Acute Myeloid Leukemia |
Chinese PLA General Hospital |
2022-12-25 | PHASE2 |
| NCT05495100 | UNKNOWN | Peripheral T Cell Lymphoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2022-08-11 | PHASE2 |
| NCT05749575 | UNKNOWN | Breast Cancer |
Sun Yat-sen University |
2023-02 | PHASE2 |
| NCT05478473 | UNKNOWN | Melanoma |
Peking University Cancer Hospital & Institute |
2022-10-27 | |
| NCT05129189 | UNKNOWN | HIV Infections |
Shanghai Public Health Clinical Center |
2022-06-29 | PHASE2 |
| NCT05137522 | UNKNOWN | Chidamide; Hemophagocytic Lymphohistiocytosis |
Beijing Friendship Hospital |
2021-07-01 | |
| NCT05747313 | UNKNOWN | Breast Cancer; Chemotherapy Effect |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2022-11-01 | PHASE1; PHASE2 |
| NCT05330364 | UNKNOWN | Acute Myeloid Leukemia |
Ge Zheng |
2021-06-01 | PHASE2 |
| NCT05400993 | UNKNOWN | Breast Cancer |
Shengjing Hospital |
2022-05-23 | PHASE2 |
| NCT05068427 | COMPLETED | Non Small Cell Lung Cancer |
Chipscreen Biosciences, Ltd. |
2021-11-23 | PHASE2 |
| NCT05056974 | COMPLETED | HIV-1 Infection |
United BioPharma |
2021-12-02 | PHASE2 |
| NCT04651127 | TERMINATED | Cervical Cancer; Cervix Cancer; Cervix Neoplasm |
Sun Yat-sen University |
2020-11-09 | PHASE1; PHASE2 |
| NCT04231448 | COMPLETED | Diffuse Large B-cell Lymphoma |
Chipscreen Biosciences, Ltd. |
2020-05-21 | PHASE3 |
| NCT04984018 | UNKNOWN | Esophageal Squamous Cell Carcinoma |
The First Affiliated Hospital of Zhengzhou University |
2021-12-01 | PHASE2 |
| NCT03574402 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Guangdong Association of Clinical Trials |
2018-07-09 | PHASE2 |
| NCT04582955 | UNKNOWN | Triple-negative Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2020-10-30 | |
| NCT05115409 | UNKNOWN | Relapsed or Refractory DLBCL |
Sun Yat-sen University |
2022-06-01 | PHASE2 |
| NCT04296786 | UNKNOWN | Cutaneous T-cell Lymphoma |
Peking Union Medical College Hospital |
2019-11-01 | PHASE2 |
| NCT05008666 | UNKNOWN | Safety and Efficacy |
Sun Yat-sen University |
2021-12-01 | PHASE2 |
| NCT04022005 | COMPLETED | Lymphoma, Large B-Cell, Diffuse |
Sun Yat-sen University |
2019-06-19 | PHASE2 |
| NCT05113355 | UNKNOWN | Neuroendocrine Tumors; Neuroendocrine Tumor Grade 3; Neuroendocrine Carcinoma; Neuroendocrine Neoplasm |
Peking Union Medical College Hospital |
2021-11-17 | PHASE2 |
| NCT05586841 | Not yet recruiting | HR+/HER2- Advanced Breast Cancer |
Beijing 302 Hospital |
2022-11-01 | Phase 1 |
| NCT05076786 | UNKNOWN | Neuroendocrine Tumors; Neuroendocrine Carcinoma |
Peking Union Medical College Hospital |
2021-10-27 | PHASE2 |
| NCT03838354 | COMPLETED | Thrombocytopenia |
Shandong University |
2021-06-01 | PHASE1; PHASE2 |
| NCT04514081 | UNKNOWN | Hodgkin Lymphoma; Anti-PD-1 Antibody Resistant |
Chinese PLA General Hospital |
2020-08-01 | PHASE2 |
| NCT05253066 | UNKNOWN | Breast Neoplasms |
Shengjing Hospital |
2022-02-25 | PHASE2; PHASE3 |
| NCT05191914 | UNKNOWN | Breast Cancer |
Liaoning Cancer Hospital & Institute |
2022-02-07 | PHASE4 |
| NCT04724239 | UNKNOWN | Advanced Microsatellite Stable Colorectal Cancer; Metastatic Microsatellite-stable Colorectal Cancer |
Sun Yat-sen University |
2021-03-11 | PHASE2 |
| NCT04414969 | UNKNOWN | Immune Checkpoint Inhibitor; Chemotherapy Effect; Epigenetic Disorder; NK/T-cell Lymphoma of Nasal Cavity |
Hunan Cancer Hospital |
2020-06-26 | PHASE2 |
| NCT04480125 | UNKNOWN | Peripheral T-cell Lymphoma |
Ruijin Hospital |
2020-06-20 | PHASE2 |
| NCT05047848 | UNKNOWN | Advanced Breast Cancer |
Liaoning Cancer Hospital & Institute |
2021-08-18 | |
| NCT04192903 | UNKNOWN | Triple-negative Breast Cancer |
Fudan University |
2019-12-25 | PHASE2 |
| NCT04831710 | UNKNOWN | Angioimmunoblastic T-cell Lymphoma |
Sun Yat-sen University |
2021-04-15 | PHASE2 |
| NCT04319601 | UNKNOWN | Angioimmunoblastic T-cell Lymphoma; Chemotherapy Effect; Chemotherapeutic Toxicity |
Zhejiang Cancer Hospital |
2020-03-13 | |
| NCT04329130 | UNKNOWN | Relapsed or Refractory Peripheral T-cell Lymphoma |
Sun Yat-sen University |
2020-03-27 | PHASE2 |
| NCT05141357 | Terminated | Non Small Cell Lung Cancer |
HUYABIO International LLC. |
2022-03-14 | Phase 2 |
| NCT03974243 | COMPLETED | Non-hodgkin's Lymphoma |
Chipscreen Biosciences, Ltd. |
2019-07-11 | PHASE1; PHASE2 |
| NCT03629873 | UNKNOWN | Lymphoma, Large B-Cell, Diffuse; Mantle Cell Lymphoma; Peripheral T Cell Lymphoma; Double-hit Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2018-02-01 | PHASE2 |
| NCT03245905 | UNKNOWN | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) |
Sun Yat-sen University |
2017-08-20 | PHASE2 |
| NCT04994210 | Recruiting | Safety and Efficacy |
Sun Yat-sen University |
2021-10-04 | Phase 2 |
| NCT04553393 | UNKNOWN | Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden |
Chinese PLA General Hospital |
2020-09-09 | PHASE1; PHASE2 |
| NCT04516655 | UNKNOWN | Central Nervous System Lymphoma |
Fudan University |
2020-09-01 | PHASE2 |
| NCT04025593 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2019-07-17 | PHASE2 |
| NCT03853044 | UNKNOWN | Angioimmunoblastic T-cell Lymphoma |
Ruijin Hospital |
2018-12-29 | PHASE2 |
| NCT03564704 | UNKNOWN | Leukemia; Leukemia, Acute; Adult Lymphoblastic Lymphoma; Leukemia, Lymphoblastic; Leukemia, T Cell; Adult Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Lymphoblastic Leukemia |
Nanfang Hospital, Southern Medical University |
2016-02-14 | PHASE2; PHASE3 |
| NCT05140616 | Recruiting | Safety and Efficacy |
The First Affiliated Hospital of Soochow University |
2021-05-31 | Phase 1|Phase 2 |
| NCT04038411 | UNKNOWN | NK/T Cell Lymphoma |
Mingzhi Zhang |
2019-04-01 | PHASE4 |
| NCT03985007 | COMPLETED | Acute Myeloid Leukemia, Relapsed, Adult |
The First Affiliated Hospital of Soochow University |
2018-01-01 | PHASE2 |
| NCT03336632 | UNKNOWN | Leukemia, Acute; MDS |
Sichuan University |
2019-01-01 | PHASE2 |
| NCT04511351 | UNKNOWN | Lymphoma |
Chinese Academy of Medical Sciences |
2014-08-01 | |
| NCT03602131 | UNKNOWN | Hodgkin Lymphoma; Non-hodgkin Lymphoma |
Sichuan University |
2019-01-01 | PHASE2 |
| NCT03611231 | UNKNOWN | Experimental Tumor |
Peking University |
2018-09-01 | PHASE2 |
| NCT03321890 | UNKNOWN | Peripheral T-cell Lymphoma |
Sun Yat-sen University |
2017-03-07 | PHASE2 |
| NCT04040491 | UNKNOWN | Peripheral T-cell Lymphoma |
Mingzhi Zhang |
2019-09-01 | PHASE4 |
| NCT03151876 | UNKNOWN | Lymphoma |
Sichuan University |
2017-06-12 | PHASE2 |
| NCT04651127 | Unknown status | Cervical Cancer|Cervix Cancer|Cervix Neoplasm |
Sun Yat-sen University |
2020-11-09 | Phase 1|Phase 2 |
| NCT04490590 | UNKNOWN | NK/T-Cell Lymphoma |
Mingzhi Zhang |
2016-10-01 | PHASE4 |
| NCT03617432 | UNKNOWN | Experimental Tumor |
Peking University |
2018-08-28 | PHASE2 |
| NCT03605056 | UNKNOWN | Multiple Myeloma |
Peng Liu |
2018-07-31 | PHASE2 |
| NCT03639168 | COMPLETED | Adenoid Cystic Carcinomas; Cisplatin |
Fudan University |
2018-06-06 | PHASE2 |
| NCT03268889 | UNKNOWN | Peripheral T Cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2017-06-15 | |
| NCT02883374 | UNKNOWN | Adenocystic Carcinoma |
Dong mei |
2016-11 | PHASE2 |
| NCT03980691 | COMPLETED | HIV/AIDS |
Guangzhou 8th People's Hospital |
2017-12-01 | PHASE1 |
| NCT03553238 | UNKNOWN | Leukemia, Acute; Leukemia, T Cell; Leukemia, Lymphoblastic |
Nanfang Hospital, Southern Medical University |
2016-02-14 | PHASE2; PHASE3 |
| NCT03820596 | COMPLETED | Safety and Efficacy |
Huiqiang Huang |
2019-03-29 | PHASE1; PHASE2 |
| NCT02733380 | UNKNOWN | Diffuse Large B-cell Lymphoma |
Henan Cancer Hospital |
2016-05 | PHASE2 |
| NCT02987244 | UNKNOWN | T Cell Non-Hodgkin's Lymphoma |
Peking Union Medical College Hospital |
2016-03 | PHASE1; PHASE2 |
| NCT03630731 | UNKNOWN | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type |
Chinese Academy of Medical Sciences |
2018-08 | PHASE2 |
| NCT03598959 | UNKNOWN | Extranodal NK/T-cell Lymphoma |
Sichuan University |
2019-01-01 | PHASE2 |
| NCT03453255 | UNKNOWN | Chemotherapy |
Chinese PLA General Hospital |
2018-01-01 | PHASE1; PHASE2 |
| NCT03201471 | UNKNOWN | Diffuse Large B Cell Lymphoma |
First Affiliated Hospital of Zhejiang University |
2017-08-20 | PHASE2 |
| NCT03410004 | UNKNOWN | Experimental |
Chinese Academy of Medical Sciences |
2018-01-25 | PHASE2 |
| NCT03494634 | UNKNOWN | Experimental Tumor |
Sun Yat-sen University |
2018-04-15 | PHASE2 |
| NCT03373019 | UNKNOWN | Chidamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasm by Histology; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, Non-Hodgkin; Cyclophosphamide; Rituximab; Gemcitabine; Cisplatin; Dexamethasone; HDAC Inhibitor |
Fudan University |
2017-12-21 | PHASE2 |
| NCT02879526 | UNKNOWN | Relapse/Refratory Peripheral T Cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2016-08 | PHASE2 |
| NCT03023358 | UNKNOWN | Peripheral T Cell Lymphoma |
Nanfang Hospital, Southern Medical University |
2017-02 | PHASE3 |
| NCT02856997 | UNKNOWN | Peripheral T Cell Lymphoma |
Yuankai Shi |
2016-09 | PHASE2 |
| NCT02878278 | UNKNOWN | Lymphoma, Extranodal NK-T-Cell; EBV |
Huiqiang Huang |
2016-09 | PHASE2 |
| NCT03273452 | UNKNOWN | Angioimmunoblastic T-cell Lymphoma |
Qingdao University |
2017-03-01 | PHASE2 |
| NCT02809573 | COMPLETED | Peripheral T-cell Lymphoma |
Chipscreen Biosciences, Ltd. |
2016-08-11 | PHASE1 |
| NCT02944812 | UNKNOWN | Peripheral T Cell Lymphoma |
Guangdong Provincial People's Hospital |
2016-03 | PHASE2 |
| NCT02753543 | UNKNOWN | Peripheral T Cell Lymphoma |
Ruijin Hospital |
2015-11 | PHASE2 |
| NCT02753647 | UNKNOWN | Diffuse Large B-cell Lymphoma |
Ruijin Hospital |
2016-04 | PHASE2 |
| NCT03105596 | UNKNOWN | B-cell Non-Hodgkin's Lymphoma |
Peking University |
2017-04-11 | PHASE2 |
| NCT02902185 | UNKNOWN | Chronic HIV Infections |
Tang-Du Hospital |
2016-11-29 | PHASE2; PHASE3 |
| NCT02886559 | UNKNOWN | AML; Relapse |
Chinese PLA General Hospital |
2016-06 | PHASE1; PHASE2 |
| NCT02482753 | COMPLETED | Breast Cancer |
Chipscreen Biosciences, Ltd. |
2015-07 | PHASE3 |
| NCT02815007 | UNKNOWN | Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer |
Yuankai Shi |
2016-06 | PHASE2 |
| NCT02513901 | COMPLETED | Chronic HIV Infections |
Tang-Du Hospital |
2015-08 | PHASE1; PHASE2 |
| NCT01836679 | COMPLETED | Non-small-cell Lung Cancer |
Chipscreen Biosciences, Ltd. |
2013-04 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2025-09-15)
Check the
Tucidinostat (Chidamide)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Tucidinostat (Chidamide) Mechanism of Action: HDAC Inhibition in Lymphocyte Research
- Tucidinostat (Chidamide): Selectivity & Specificity
- Tucidinostat (Chidamide) Working Concentration | Cell Culture | Treatment
- Tucidinostat (Chidamide) Solubility in DMSO
- Tucidinostat (Chidamide) Stock Solution
- Tucidinostat (Chidamide) Storage
- Tucidinostat (Chidamide) Stability
- Tucidinostat (Chidamide) Combination Database
- Tucidinostat (Chidamide) Molecular Weight
- Tucidinostat (Chidamide) SMILES
- Tucidinostat (Chidamide) CAS Number
- Tucidinostat (Chidamide) Chemical Structure (2D and 3D)
- Tucidinostat (Chidamide) IC50 for Cell-based and Cell-free Assays
- Tucidinostat (Chidamide) APExBIO (C6369)? Try a better option.
- Tucidinostat (Chidamide) MedChemExpress (HY-109015)? Try a better option.
- Tucidinostat (Chidamide) Sigma (SML4257)? Try a better option.
- Tucidinostat (Chidamide) Cayman (13686)? Try a better option.
- Tucidinostat (Chidamide) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.